These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15095769)

  • 1. Prevention could be less cost-effective than cure: the case of hepatitis C screening policies in France.
    Loubière S; Rotily M; Moatti JP
    Int J Technol Assess Health Care; 2003; 19(4):632-45. PubMed ID: 15095769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the cost-effectiveness of hepatitis C screening strategies in France.
    Deuffic-Burban S; Huneau A; Verleene A; Brouard C; Pillonel J; Le Strat Y; Cossais S; Roudot-Thoraval F; Canva V; Mathurin P; Dhumeaux D; Yazdanpanah Y
    J Hepatol; 2018 Oct; 69(4):785-792. PubMed ID: 30227916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison.
    Sutton AJ; Edmunds WJ; Gill ON
    BMC Public Health; 2006 Jun; 6():170. PubMed ID: 16803622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups.
    Nakamura J; Terajima K; Aoyagi Y; Akazawa K
    Tohoku J Exp Med; 2008 May; 215(1):33-42. PubMed ID: 18509233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting.
    Jülicher P; Galli C
    J Med Econ; 2018 Jan; 21(1):1-10. PubMed ID: 28881157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.
    Lin OS; Keeffe EB; Sanders GD; Owens DK
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1159-72. PubMed ID: 15153169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered.
    Younossi Z; Blissett D; Blissett R; Henry L; Younossi Y; Beckerman R; Hunt S
    Liver Int; 2018 Feb; 38(2):258-265. PubMed ID: 28719013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population.
    Ethgen O; Sanchez Gonzalez Y; Jeanblanc G; Duguet A; Misurski D; Juday T
    J Med Econ; 2017 Feb; 20(2):162-170. PubMed ID: 27590836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers.
    Rattay T; Dumont IP; Heinzow HS; Hutton DW
    Gastroenterology; 2017 Dec; 153(6):1531-1543.e2. PubMed ID: 29074450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populations.
    Tramarin A; Gennaro N; Compostella FA; Gallo C; Wendelaar Bonga LJ; Postma MJ
    Curr Pharm Des; 2008; 14(17):1655-60. PubMed ID: 18673188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults.
    Singer ME; Younossi ZM
    Am J Med; 2001 Dec; 111(8):614-21. PubMed ID: 11755504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic assessment of an anti-HCV screening program in Italy.
    Ruggeri M; Coretti S; Gasbarrini A; Cicchetti A
    Value Health; 2013; 16(6):965-72. PubMed ID: 24041346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the universal population Hepatitis C virus screening a cost-effective strategy? A systematic review of the economic evidence.
    Ledesma F; Buti M; Domínguez-Hernández R; Casado MA; Esteban R
    Rev Esp Quimioter; 2020 Aug; 33(4):240-248. PubMed ID: 32510188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of strategies for hepatitis C screening in French blood recipients.
    Jusot JF; Colin C
    Eur J Public Health; 2001 Dec; 11(4):373-9. PubMed ID: 11766476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
    JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection.
    Deuffic-Burban S; Abiteboul D; Lot F; Branger M; Bouvet E; Yazdanpanah Y
    Gut; 2009 Jan; 58(1):105-10. PubMed ID: 18824553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.
    Wong JB; Bennett WG; Koff RS; Pauker SG
    JAMA; 1998 Dec 23-30; 280(24):2088-93. PubMed ID: 9875876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective.
    Loubière S; Rotily M; Durand-Zaleski I; Costagliola D
    Vox Sang; 2001 May; 80(4):199-204. PubMed ID: 11438026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget impact analysis on the introduction of a guideline based hepatitis B and C screening into a routine check-up in the German primary care setting.
    Barth C; Neusser S; Biermann J; Wasem J; Berg T; Wiegand J; Wolffram I; Petroff D; Aidelsburger P; Grünbauer A; Neumann A
    Scand J Gastroenterol; 2018 Jan; 53(1):76-82. PubMed ID: 29065740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness and population outcomes of general population screening for hepatitis C.
    Coffin PO; Scott JD; Golden MR; Sullivan SD
    Clin Infect Dis; 2012 May; 54(9):1259-71. PubMed ID: 22412061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.